GSK Reaches ‘First Base’ In Hep B Functional Cure But Has More To Prove

9% Disease Free After Phase II Study

Hepatitis B virus
Hepatitis B has so far proven very difficult to suppress - but GSK is hoping to achieve a functional cure for more patients in its Phase III study • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Clinical Trials

More from R&D